Mineralys Therapeutics Announces $120 Million Private Placement Financing
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.
Related news for (MLYS)
- Midday Movers: Biotech Breakouts, Special Payouts, and Strategic Power Plays
- Lasers, Lungs & Leapfrogs: Innovation Sparks Market Moves as Healthcare Stocks Surge
- Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
- Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
- Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection